Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 1999

View Archived Issues

Lexicon Genetics signs knockout mouse agreement with Millennium

Oxis receives U.S. patent for lipid-soluble antioxidants for skin protection

Cantab highlights achievements in development programs during Q2 1999

Gemini and Affymetrix collaborate to develop osteoporosis risk test

Potential disease-altering therapy for Parkinson's to be assessed in comparison trial

Corvas ends option agreement with Vascular Genomics

Effects of new cognition enhancer, T-588, on hippocampal CA1 neurons in rat brain slices

Fujisawa and Discovery Therapeutics enter agreement for cardiovascular drug development

Herceptin approved and launched in Switzerland

New erythromycin derivatives for treating infections caused by acid-fast bacteria

Merck to acquire Sibia Neurosciences

Paxene launched in the Czech Republic

Gentamicin may offer hope for Duchenne's muscular dystrophy patients

MorphiDex not approvable, FDA says

Celgene receives patent, completes trial enrollment for ADD/ADHD product

Unigene awarded U.S. patent for oral calcitonin product

U.K. academics isolate novel cytotoxic agent from cyanobacterium

Cell Therapeutics discloses CT-2412 and related compounds for increasing drug bioavailability

Daiichi reports novel cytokine production inhibitors in patent literature

Novo Nordisk synthesizes potassium channel modulators for endocrine diseases

Guilford continues research into NAALDase inhibitors

Hoechst Marion Roussel reveals new anticoagulants with advantages over heparin

Beta-blocker proxodolol, a safe and effective treatment for glaucoma

Anecortave acetate: a novel angiostatic steroid for the treatment of ocular neovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...